Apellis Pharmaceuticals, Inc. - Common Stock (APLS)

It's reaching into its coffers for a $5.6 billion acquisition.

In a move that signals a decisive shift away from its traditional focus on neuroscience, Biogen (NASDAQ: BIIB) announced today, March 31, 2026, that it has entered into a definitive agreement to acquire Apellis Pharmaceuticals (NASDAQ: APLS) for approximately $5.6 billion in cash. The deal, valued at $41 per

This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.

Apellis (APLS) Q4 2025 Earnings Call Transcript

Apellis Pharmaceuticals exemplifies the GARP strategy with strong revenue growth, fair biotech valuation, and solid profitability margins.

SAN JOSE, CA – December 11, 2025 – In a pivotal move poised to redefine the landscape of semiconductor design and cybersecurity, Arteris, Inc. (NASDAQ: APLS), a leading provider of system IP for accelerating chiplet and System-on-Chip (SoC) creation, today announced its definitive agreement to acquire Cycuity, Inc., a pioneer in semiconductor cybersecurity assurance. This [...]

Apellis Pharmaceuticals exemplifies the GARP strategy with strong commercial growth, recent profitability, and a valuation attractive relative to biotech peers.

Discover Apellis Pharmaceuticals (APLS), an affordable growth stock with strong revenue growth, fair valuation, and solid financial health for investors.

Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism.

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Apellis Pharmaceuticals (APLS) Q3 2025 earnings crushed estimates, driven by strong drug sales and a major partnership payment. The company achieved profitability and positive market reaction.